187 related articles for article (PubMed ID: 31454248)
21. Tumor-infiltrating FoxP3+ Tregs and CD8+ T cells affect the prognosis of hepatocellular carcinoma patients.
Huang Y; Wang FM; Wang T; Wang YJ; Zhu ZY; Gao YT; Du Z
Digestion; 2012; 86(4):329-37. PubMed ID: 23207161
[TBL] [Abstract][Full Text] [Related]
22. Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells.
Jahan N; Talat H; Curry WT
Neuro Oncol; 2018 Jan; 20(1):44-54. PubMed ID: 29016879
[TBL] [Abstract][Full Text] [Related]
23. Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8
Peng W; Williams LJ; Xu C; Melendez B; McKenzie JA; Chen Y; Jackson HL; Voo KS; Mbofung RM; Leahey SE; Wang J; Lizee G; Tawbi HA; Davies MA; Hoos A; Smothers J; Srinivasan R; Paul EM; Yanamandra N; Hwu P
Clin Cancer Res; 2019 Nov; 25(21):6406-6416. PubMed ID: 31371342
[TBL] [Abstract][Full Text] [Related]
24. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
Fu Y; Liu S; Zeng S; Shen H
J Exp Clin Cancer Res; 2019 Sep; 38(1):396. PubMed ID: 31500650
[TBL] [Abstract][Full Text] [Related]
25. VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma.
Zhang M; Pang HJ; Zhao W; Li YF; Yan LX; Dong ZY; He XF
BMC Cancer; 2018 May; 18(1):511. PubMed ID: 29720116
[TBL] [Abstract][Full Text] [Related]
26. Anti-tumor activity and mechanism of oligoclonal hepatocellular carcinoma tumor-infiltrating lymphocytes
Wang WC; Zhang ZQ; Li PP; Ma JY; Chen L; Qian HH; Shi LH; Yin ZF; Sun B; Zhang XF
Cancer Biol Ther; 2019; 20(9):1187-1194. PubMed ID: 31018748
[No Abstract] [Full Text] [Related]
27. Cancer cell-intrinsic STING is associated with CD8 + T-cell infiltration and might serve as a potential immunotherapeutic target in hepatocellular carcinoma.
Zhang Y; Zhai Q; Feng X; Chen D; Lu Y; Hu J; Xie H; Zhou L; Wu J; Zheng S
Clin Transl Oncol; 2021 Jul; 23(7):1314-1324. PubMed ID: 33502741
[TBL] [Abstract][Full Text] [Related]
28. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection.
Piconese S; Valzasina B; Colombo MP
J Exp Med; 2008 Apr; 205(4):825-39. PubMed ID: 18362171
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy of hepatocellular carcinoma: is there a place for regulatory T-lymphocyte depletion?
Cany J; Tran L; Gauttier V; Judor JP; Vassaux G; Ferry N; Conchon S
Immunotherapy; 2011 Apr; 3(4 Suppl):32-4. PubMed ID: 21524167
[TBL] [Abstract][Full Text] [Related]
30. Prediction of recurrence and survival in hepatocellular carcinoma based on two Cox models mainly determined by FoxP3+ regulatory T cells.
Lin SZ; Chen KJ; Xu ZY; Chen H; Zhou L; Xie HY; Zheng SS
Cancer Prev Res (Phila); 2013 Jun; 6(6):594-602. PubMed ID: 23599540
[TBL] [Abstract][Full Text] [Related]
31. Tumor antigen pulsed dendritic cells enhance the cytolytic activity of tumor infiltrating lymphocytes in human hepatocellular cancer.
Friedl J; Stift A; Paolini P; Roth E; Steger GG; Mader R; Jakesz R; Gnant MF
Cancer Biother Radiopharm; 2000 Oct; 15(5):477-86. PubMed ID: 11155819
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy in hepatocellular carcinoma.
Buonaguro L; Mauriello A; Cavalluzzo B; Petrizzo A; Tagliamonte M
Ann Hepatol; 2019; 18(2):291-297. PubMed ID: 31047849
[TBL] [Abstract][Full Text] [Related]
33. Science gone translational: the OX40 agonist story.
Weinberg AD; Morris NP; Kovacsovics-Bankowski M; Urba WJ; Curti BD
Immunol Rev; 2011 Nov; 244(1):218-31. PubMed ID: 22017441
[TBL] [Abstract][Full Text] [Related]
34. OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy.
Shibahara I; Saito R; Zhang R; Chonan M; Shoji T; Kanamori M; Sonoda Y; Kumabe T; Kanehira M; Kikuchi T; So T; Watanabe T; Takahashi H; Iwabuchi E; Tanaka Y; Shibahara Y; Sasano H; Ishii N; Tominaga T
Mol Cancer; 2015 Feb; 14():41. PubMed ID: 25744203
[TBL] [Abstract][Full Text] [Related]
35. 14-3-3ζ delivered by hepatocellular carcinoma-derived exosomes impaired anti-tumor function of tumor-infiltrating T lymphocytes.
Wang X; Shen H; Zhangyuan G; Huang R; Zhang W; He Q; Jin K; Zhuo H; Zhang Z; Wang J; Sun B; Lu X
Cell Death Dis; 2018 Feb; 9(2):159. PubMed ID: 29415983
[TBL] [Abstract][Full Text] [Related]
36. Increased frequency of CD4+CD25(high)FoxP3+ regulatory T cells in patients with hepatocellular carcinoma.
Feng X; Li B; Ye H; Long D
Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):309-14. PubMed ID: 21633918
[TBL] [Abstract][Full Text] [Related]
37. Regulatory T cell depletion enhances tumor specific CD8 T-cell responses, elicited by tumor antigen NY-ESO-1b in hepatocellular carcinoma patients, in vitro.
Zhang HH; Mei MH; Fei R; Liao WJ; Wang XY; Qin LL; Wang JH; Wei L; Chen HS
Int J Oncol; 2010 Apr; 36(4):841-8. PubMed ID: 20198327
[TBL] [Abstract][Full Text] [Related]
38. Liver-infiltrating CD8(+) lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma.
Ramzan M; Sturm N; Decaens T; Bioulac-Sage P; Bancel B; Merle P; Tran Van Nhieu J; Slama R; Letoublon C; Zarski JP; Jouvin-Marche E; Marche PN; Leroy V
Liver Int; 2016 Mar; 36(3):434-44. PubMed ID: 26215124
[TBL] [Abstract][Full Text] [Related]
39. Tumor eradicated by combination of imiquimod and OX40 agonist for in situ vaccination.
Chu Y; Li R; Qian L; Liu F; Xu R; Meng F; Ke Y; Shao J; Yu L; Liu Q; Liu B
Cancer Sci; 2021 Nov; 112(11):4490-4500. PubMed ID: 34537997
[TBL] [Abstract][Full Text] [Related]
40. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
Messenheimer DJ; Jensen SM; Afentoulis ME; Wegmann KW; Feng Z; Friedman DJ; Gough MJ; Urba WJ; Fox BA
Clin Cancer Res; 2017 Oct; 23(20):6165-6177. PubMed ID: 28855348
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
